Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $80.4 million.

  • Relay Therapeutics' Operating Expenses fell 1658.0% to $80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.4 million, marking a year-over-year decrease of 1392.1%. This contributed to the annual value of $382.5 million for FY2024, which is 403.24% down from last year.
  • Relay Therapeutics' Operating Expenses amounted to $80.4 million in Q3 2025, which was down 1658.0% from $77.5 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Operating Expenses ranged from a high of $194.4 million in Q2 2021 and a low of $43.4 million during Q1 2021
  • Moreover, its 5-year median value for Operating Expenses was $86.2 million (2022), whereas its average is $89.5 million.
  • In the last 5 years, Relay Therapeutics' Operating Expenses surged by 60141.06% in 2021 and then crashed by 5979.1% in 2022.
  • Relay Therapeutics' Operating Expenses (Quarter) stood at $68.3 million in 2021, then rose by 7.05% to $73.1 million in 2022, then increased by 26.11% to $92.2 million in 2023, then decreased by 7.83% to $85.0 million in 2024, then decreased by 5.4% to $80.4 million in 2025.
  • Its Operating Expenses was $80.4 million in Q3 2025, compared to $77.5 million in Q2 2025 and $92.5 million in Q1 2025.